Zouboulis CC, et al. - Researchers evaluated the response and tolerability of long-term adalimumab in hidradenitis suppurativa/acne inversa (HS). The durations of PIONEER I/II periods A, B, and open-label extension (OLE) were 12, 24, and ≥ 52 weeks, respectively. As per data, there was a sustained improvement in lesion counts, skin pain, and Dermatology Life Quality Index (DLQI). Findings suggested a similarity in the safety profile throughout the OLE and the profiles observed in the PIONEER studies. For long-term control of moderate-to-severe HS, continuous weekly dosing with adalimumab 40 mg was a reasonable treatment option.